INS and type 2 diabetes mellitus: This compares favourably with data from a RCT, in which 33% of patients with type 2 diabetes achieved this target using bid BIAsp 30 (approximately one-third of patients were previously treated with basal insulin) after 26 weeks of therapy (21).